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Abstract  
Aims and methods: Even if treatment controls symptoms, patients with heart failure may 
still be congested. We recorded clinical and ultrasound (lung B-lines; inferior vena cava 
(IVC) diameter; internal jugular vein diameter before and after Valsalva (JVD ratio)) features 
of congestion in patients with heart failure during a routine check-up to assess their 
prevalence, relationships and prognostic significance. 
 
Results: Of 342 patients, predominantly in NYHA I or II (257; 75%), who attended, 242 
(71%) had at least one feature of congestion, either clinical (139; 41%) or by ultrasound (199; 
58%). Amongst patients (n=203, 59%) clinically free of congestion, 31 (15%) had >14 B-
lines, 57 (29%) had a dilated IVC (> 2.0 cm), 38 (20%) had an abnormal JVD ratio (<4), 87 
(43%) had at least one of these and 27 (13%) had two or more.  
 
During a median follow-up of 234 (IQR: 136-351) days, 60 patients (18%) died or were 
hospitalized for heart failure. In univariable analysis, each clinical and ultrasound measure of 
congestion was associated with increased risk but, in multivariable models, only higher NT-
proBNP and IVC, and lower JVD ratio, were associated with the composite outcome.  
 
Conclusions: Many patients with chronic heart failure with few symptoms have objective 
evidence of congestion and this is associated with an adverse prognosis.  Whether using these 
measures of congestion to guide management improves outcomes requires investigation.  
 
 
Key words: lung ultrasound, congestion, B-lines, IVC, jugular vein ultrasound. 
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Introduction 
Congestion is a common cause of hospitalization for patients with heart failure (1). Poorly 
controlled congestion may also lead to unfavourable atrial and ventricular remodelling, 
clinical progression of disease, recurrent admissions, and an increase in mortality (2-5).  
 
Accurately quantifying congestion is difficult (6), and may commonly be missed unless it is 
obvious (7-9). Also, some clinical features of congestion are not specific for cardiac 
dysfunction and may occur with many other conditions, including nephrotic syndrome, liver 
or thyroid disease, or venous insufficiency, or as a side-effect of commonly prescribed drugs 
to treat hypertension, such as calcium channel blockers, or diabetes, such as glitazones.   
 
Congestion can only be managed appropriately if it is recognised (10).  Detection of 
congestion before it becomes clinically overt in patients with heart failure should lead to 
better management, particularly with respect to diuretic dose (11, 12). However, many 
apparently stable out-patients with heart failure without clinical evidence of congestion might 
have sub-clinical congestion detected by biomarkers, ultrasound or other non-invasive 
techniques. 
 
We therefore investigated the prevalence and clinical relevance of congestion in out-patients 
with chronic heart failure (CHF) attending a routine follow-up clinic using ultrasound to 
detect, contemporaneously, pulmonary interstitial oedema (lung B-lines) and intra-vascular 
fluid overload (inferior vena cava (IVC) diameter, and the internal jugular vein diameter 
before and after a Valsalva manoeuvre (JVD ratio) (13-18). 
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Methods 
 
Study Population  
Between April 2016 and March 2017, we enrolled consecutive patients with a prior clinical 
diagnosis of heart failure attending a routine follow-up visit to a heart failure clinic serving a 
local population of about 550,000 people. In our clinic, stable out-patients on optimal 
treatment are reviewed by heart failure specialist nurses and doctors at regular intervals, 
usually every 12 months, unless an appointment is requested sooner by the patient, physician 
or specialist nurse. All subjects gave their written informed consent. The study conformed to 
the principles outlined in the Declaration of Helsinki and was approved by relevant ethical 
bodies. 
 
Patients provided a detailed clinical history and had blood tests (including haematology, 
biochemistry profile and NT-proBNP), ECGs and echocardiograms done on the same day. 
The information was systematically recorded in a dedicated electronic health record stored on 
a secure NHS server. Treating clinicians had access to the entire echocardiographic exam 
performed prior to the visit, including B-lines, IVC and JVD examination; however, they 
were blinded to blood results, including NT-proBNP. 
 
The minimum follow-up period was three months. The primary outcome of interest was a 
composite of all-cause mortality or HF hospitalization. Our hospital is the only one in the 
region offering acute medical services. With consent obtained from patients, we have access 
to both primary and secondary care records. Data regarding deaths and hospitalisations were 
collected from the hospital’s electronic systems, supplemented by information from discharge 
letters, patients, and their family doctors. For the purpose of this study, a hospitalisation was 
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considered due to heart failure only if HF was mentioned as primary diagnosis on the 
discharge letter by the discharging physician from our hospital. 
 
Clinical assessment  
Clinical examinations were performed before echocardiography. A clinical congestion score 
was applied, based on lung auscultation (normal, presence of basal, mid zone or diffuse 
crackles), JVP (not visible, raised 1-4 cm, raised to earlobe), and peripheral oedema (none, 
ankles, below or above knees) with one point attributed for each degree of severity. When the 
total score was 0, patients were considered clinically uncongested; those scoring >3 were 
defined as severely congested (4).  
 
Echocardiographic measurements 
Echocardiography was performed by an experienced operator (AB) using a Vivid Seven (GE 
Health care, UK) system operating at 1.7-3.4MHz. Doppler tracings and two-dimensional 
images were obtained from parasternal long- and short-axis, apical and subcostal views. 
Echocardiograms were stored and reviewed by an experienced operator (PP) using an 
EchoPAC station (GE Health care, UK). LVEF was measured using Simpson’s biplane 
method. LA volume was measured in the four chamber view and indexed to body surface 
area (LAVI). Tricuspid annular plane systolic excursion (TAPSE) was used to assess right 
ventricular (RV) systolic function. The maximum trans-tricuspid systolic gradient was also 
measured (based on the modified Bernoulli equation, ΔP = Max TR velocity2 x 4). With the 
patient in the supine position, the maximum inferior vena cava (IVC) diameter during the 
respiratory cycle was measured between one and three centimeters before merger with the 
right atrium. The IVC collapse following deep inspiration (a brief sniff) was visually 
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estimated as >50 or <50 %. Intrahepatic veins were recorded as visible, and their maximum 
diameter during the cardiac cycle was measured, or not visible.   
 
Jugular Vein ultrasound 
With the patient semi-recumbent at 45°, jugular venous (JV) ultrasound was performed as 
previously described (19). Briefly, with the patient reclining and head and neck elevated at 
45°, a linear high frequency probe (10 MHz) was placed on the left side of the neck below the 
angle of the jaw and moved inferiorly toward the angle of Louis until the left internal JV was 
identified.  Internal JV diameter and its changes were then measured continuously by M-
mode or in the 2-dimensional frame at rest (expiratory phase), during a Valsalva manoeuvre 
(performed by forceful expiration against a closed glottis) and, finally, during deep 
inspiration. The ratio between maximum JV diameter during Valsalva and diameter at rest 
was calculated (JVD ratio).  
 
B-lines 
B-lines, or lung comets, are echogenic, perpendicular signals arising from the pleura during 
lung ultrasound, often indicating the presence of extravascular lung water (20, 21). Although 
different methods to assess them have been proposed, we scanned a total of 28 chest sites 
(from the second to the fifth intercostal space on the right hemithorax, and from the second to 
the fourth intercostal space on the left hemithorax along the parasternal, mid-clavicular, 
anterior axillary and mid-axillary lines (22)) and counted the number of B-lines found at each 
site. All patients were analysed in a near-supine position with the same probe used for 
echocardiography. B-lines were recorded for at least 5 beats for each chest site, and images 
were subsequently stored and reviewed off-line by an experienced operator (PP).  
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We defined congestion by ultrasound as an abnormal JVD ratio (<4), a distended IVC (>20 
mm) or B-lines above or equal to the lower boundary of the highest tercile (>14). 
 
Statistical methods 
Categorical data are presented as number and percentages; normally distributed continuous 
data as mean + SD and non-normally distributed continuous variables as median and 
interquartile range (IQR). We present the ultrasound variables as median and IQR to 
demonstrate the distribution of each variable within the studied population.  
 
Patients with HF were grouped by phenotypes (heart failure with reduced (HFrEF, 
LVEF<40%), mid-range (HFmrEF, LVEF 40-49%), or preserved (HFpEF, LVEF>50%) 
LVEF) or by terciles of B-lines, IVC and JVD ratio or NT-proBNP. One-way ANOVA and 
Kruskal-Wallis tests were used to compare continuous variables between groups depending 
on the normality of the distribution, and the chi-squared test was used for categorical 
variables.  
 
Analysis 1. Two different multivariable Cox proportional hazard regression models were 
used to investigate the relationship between JVD ratio, IVC and B-lines, and prognosis using 
a limited number of variables to prevent statistical overfitting. In Model A (Clinical Model) 
five candidate variables of interest (age, NYHA class III vs I/II, urea, haemoglobin and log 
[NT-proBNP]) were chosen prospectively in addition to each ultrasound measurement of 
congestion.  For model B (Echocardiographic Model), the three echocardiographic variables 
that were most strongly associated with prognosis in univariable analysis (highest 𝜒2) were 
included in addition to each ultrasound measurement of congestion, age and Log [NT-
proBNP].  
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Forward and backward procedures were used to determine which variables independently 
predicted the primary composite outcome. Assumptions of the models were tested, such as 
multicolinearity and proportional hazards.  
 
Analysis 2 (Discrimination and reclassification improvement analysis). In order to estimate 
the predictive value of the different variables of interest, we constructed a basic a priori 
model, which included variables of clinical interest that are easily available in a heart failure 
clinic (age, sex, NYHA (III vs II/I), creatinine, haemoglobin and LVEF) and then tested the 
added value of each measure (and combinations of measures) of congestion, in turn. The 
variables of interest added to the basic model were: log[NT-proBNP]; and/or ultrasound 
measurements of congestion (either IVC diameter, JVD ratio or B-lines). The incremental 
value of the variables (the model’s cumulative discrimination) was measured using Harrell's 
C statistic: the mean values of IVC diameter, JVD ratio and logNT-proBNP were used to 
impute missing values. The higher discriminative value associated with the net 
reclassification improvement (NRI) and the integrated discrimination improvement (IDI) for 
ultrasound measurements of congestion were assessed at 1 year of follow-up.  
 
Kaplan-Meier curves with the log-rank statistic were used to illustrate outcome. 
 
All analyses were performed using SPSS and Stata software. A 2-sided P value < 0.05 was 
considered statistically significant. 
 
Results 
Patient characteristics (n=342, table 1) 
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Median age (inter-quartile range [IQR]) was 75 [68-82] years, and median plasma NT-
proBNP was 1275 [461-2659] ng/L. Mean LVEF was 45 (+14) %. LVEF was <40% in 124 
patients, 40-49% in 68 patients (39 previously had LVEF <40%) and 150 had LVEF >50% 
(45 previously had LVEF <40%). Approximately 85% of patients were treated with beta-
blockers and ACE-inhibitors and 75% were taking loop diuretics.  
Some evidence of clinical congestion was similarly common amongst the three heart failure 
phenotypes (36-44%), although patients with HFrEF were more likely to be treated with a 
loop diuretic and mineralocorticoid antagonist that those with HFmrEF or HFpEF.  There 
was no difference in the number of patients amongst the phenotypes who had their diuretics 
increased or decreased at the clinical visit.  There was no difference between the phenotypes 
in ultrasound measures of congestion (Table 1). 
 
Clinical vs ultrasound congestion 
It was possible to measure B-lines in all patients, whilst the IVC was not visualised in 7 (2%). 
Due to a technical problem (the 10 MHz linear probe needed repair) it was not possible to 
assess JVD ratio in 23 patients (7%). 
Congestion by ultrasound was more common, and more severe, with increasing severity of 
clinical congestion (Table 1 supplementary). When clinical congestion was severe, B-lines 
were almost ubiquitous, IVC was dilated in around 90% of cases, and JVD ratio was 
abnormal in >80% patients.  However, of the 187 patients with complete ultrasound data who 
had no clinical sign of congestion, 87 (47%) had at least 1 sign of congestion on ultrasound, 
with 10 (5%) having all three ultrasonic signs of congestion (figure 1).    
Correlations amongst ultrasound measures of congestion were generally modest. Correlations 
between ultrasound measures of congestion and age, haemoglobin, left atrial volume, 
estimated PA pressure and NT-proBNP were also modest. Ultrasound measures of congestion 
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were poorly correlated with LVEF. There was an inverse correlation between body mass 
index (BMI) and B-lines, but not with JVD ratio or IVC diameter (table 2 and table 2a-d and 
3 supplementary).  
Compared to patients in sinus rhythm, those in atrial fibrillation had more severe congestion 
by ultrasound (table 3 supplementary). 
 
Outcome   
There were 60 primary outcome events during a median follow-up of 234 (IQR: 136-351) 
days. The first qualifying event was hospitalisation due to worsening HF in 35 patients and 
death in 25 patients.  
 
Analysis 1. In univariable Cox regression analysis, worsening clinical congestion and 
increasing B-lines were associated with an increased risk of events (Table 4 supplementary 
and Figure 2).  In multivariable analysis, increasing log [NT-proBNP] and IVC diameter, or 
decreasing JVD ratio (with increasing urea) were the only variables independently related to 
an adverse outcome in both Model A (Table 3a) and Model B (Table 3b).  
 
Analysis 2. Discrimination and reclassification improvement analysis 
 
For the entire cohort of patients, the baseline clinical model yielded a c-index 0.74, which did 
not increase significantly when logNT-proBNP or ultrasound measures of congestion were 
added singly or in combination. In contrast, adding any of logNT-proBNP or ultrasound 
measures of congestion improved prediction of outcome at 1 year and increased IDI and NRI. 
Adding JVD ratio to a model that included logNTproBNP further improved re-classification 
by IDI only. The greatest improvement by IDI was when B-lines and JVD ratio were 
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simultaneously added (Table 4). 
 
Patients who were simultaneously in the top tercile of NT-proBNP (>2045 ng/L) and the 
highest terciles of B-lines, JVD ratio or IVC diameter had the worst outcomes (Figure 3).  
 
Discussion 
This analysis confirms previous reports suggesting that increasing IVC diameter (17, 18) or 
number of B-lines by ultrasound (13-15) identify patients with CHF who have higher plasma 
concentrations of NT-proBNP and a greater risk of an adverse outcome, regardless of their 
LVEF. We also confirm the clinical and prognostic utility of a novel ultrasonic method to 
assess fluid overload; the JVD ratio (16, 23). However, probably the most important finding 
was that nearly 50% of ambulatory patients with CHF thought not to be congested had 
evidence of congestion on ultrasound and that when multiple such measures are present the 
prognosis is poor.  
 
In the current era, practising evidence-based medicine should be the norm; however 
management of clinical congestion, and the use of diuretics in patients with heart failure, is 
still an inexact medical art.  For patients hospitalized with cardiac decompensation, some 
clinical algorithms for the evaluation and assessment of congestion have been proposed, but 
they are constructed on subjective variables, such as symptoms and signs, and obviously open 
to bias (24, 25). For patients with CHF, recommendations to detect, monitor and treat 
congestion during follow-up are rather vague, and will vary according to local organisation 
and resources (26).  
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NT-proBNP is a consistently strong prognostic marker for patients with stable CHF, although 
its prognostic utility in the acute setting is more doubtful (27, 28) and values may be affected 
by comorbidities, such as atrial fibrillation and renal dysfunction. Several randomized clinical 
trials have assessed whether serial measurements of plasma natriuretic peptide concentrations 
might be used to guide treatment for HF; their results are controversial, perhaps because 
guideline-recommended treatment is effective and perhaps because trials of a natriuretic 
peptide-guided strategy have not lead to substantial differences in therapy between 
randomised groups (29-30). Natriuretic peptides are a measure of congestion rather than of 
cardiac dysfunction or its cause, which is both their strength and weakness; their strength 
because congestion is strongly related to prognosis; their weakness because congestion may 
be renal or cardiac in origin to varying degrees and because it is important to know the cause 
of heart failure in order to decide on treatment. It is also possible that renal dysfunction leads 
to reduced clearance of NT-proBNP and an increase in plasma concentration unrelated to 
congestion, although it is likely that reduced renal clearance of NT-proBNP is associated with 
diuretic resistance and reduced salt and water excretion. However, ultrasound can determine 
the presence of congestion and quantify similarly in the presence or absence of renal 
dysfunction. Clearly, a measurement of renal function is important to determine both the 
reason for an elevated NT-proBNP and the cause of congestion. Whether a strategy starting 
with measuring NT-proBNP and urea/creatinine first followed by ultrasound evaluation when 
results indicate congestion; or whether ultrasound could supplant natriuretic peptides is 
worthy of investigation. In a primary-care setting, blood markers are likely to be the preferred 
strategy for the evaluation of congestion. However, in a cardiology clinic where 
echocardiography is readily available, obtaining an instantaneously available measurement of 
congestion along with the opportunity to gather information on valve and ventricular 
function, ultrasonic evaluation might be favoured. 
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Absence of congestion on ultrasound might be a measure of treatment success associated 
with an excellent outcome and might also help avoid over-treatment especially for patients 
who have other reasons for their breathlessness such as chronic obstructive pulmonary 
disease. On the other hand, persistence of sub-clinical congestion might be a measure of 
inadequate treatment. Quantifying congestion by ultrasound might also provide an objective 
measure of response to novel treatments, help guide the intensity of diuretic use, facilitate 
personalised therapy tailored to the individual patient’s needs and decide on the frequency of 
follow-up appointments or determining when it might be appropriate to reassure patients and 
discharge them back to primary care. The increasing availability of hand-held, low-cost 
ultrasound devices and the demonstration that skills can be rapidly taught to people with little 
or no prior experience increases the feasibility of this approach (31).  
 
Limitations 
 
In our cohort, agreement amongst different methods for assessing congestion by ultrasound 
was modest when clinical congestion was absent, but increased as clinical congestion became 
more evident. This might be because the cut-offs used to define “congestion by ultrasound” 
were not optimal, or it might be because congestion is heterogeneous amongst different 
organs and compartments. Some patient characteristics, such as a high BMI, might decrease 
the number of identifiable lung comets, perhaps reflecting less advanced disease (32) or a 
technical obstruction to their visualisation (14). High BMI or non-uniform body anatomy 
could affect IVC assessment, or the visualization of intra-hepatic veins.  
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This was a single centre study of consecutive patients previously diagnosed with HF, 
regardless of their LVEF. In the absence of a general consensus on how to diagnose HFpEF, 
it might be possible that our population of patients with HFpEF differs from those from other 
centres.  
 
There is no recommendation that HF treatment should be guided by signs of congestion on 
ultrasound, and not all physicians can interpret B-lines, or JVD ratio; however, it is still 
possible that evidence of congestion on ultrasound might have led to adjustments in treatment 
in a few patients, and particularly to an increase in diuretic dose. This might have affected our 
final results. None of our patients had received novel treatments such as sacubitril/valsartan 
prior to follow-up. Compared to ACE-I, sacubitril/valsartan might decrease NT-proBNP (33).  
 
The number of patients enrolled, and events recorded, are modest: more studies will be 
needed to clarify whether measuring the upstream consequences of a dysfunctional right 
ventricle (reduced JVD ratio or dilated IVC diameter) provides more powerful prognostic 
information than measuring the upstream consequences of a dysfunctional left ventricle 
(greater number of B-lines). Similarly, more work is needed to see whether these novel 
ultrasound methods might be used to identify different phenotypes of patients with heart 
failure, who need different therapies. 
 
However, to the best of our knowledge this is the largest prospective study evaluating B-lines 
in out-patients with HF (13), also coupled with a detailed and comprehensive clinical, 
ultrasound and biomarker evaluation of congestion.  
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B-lines are not specific evidence of lung congestion and may also reflect parenchymal lung 
disease. We enrolled patients whether or not they had co-morbid lung disease. This might 
have increased the number of B-lines measured in some patients. We also assessed B-lines in 
the near-supine position, exploring 28 antero-lateral chest zones, using clips recording 5 heart 
beats only: the number of B-lines may vary with gravity and postural changes, and might 
increase with longer evaluations (34). Findings might have been different if other protocols 
(ie, the 8 antero-lateral chest sites) were used.  
 
We did not study the prevalence of congestion by ultrasound in a control group. It is likely 
that some people without other evidence of heart or lung disease will have an abnormal 
number of B-lines, or dilated IVC (35).  
 
Conclusions 
Many patients with heart failure free of clinically overt congestion remain sub-clinically 
congested; these patients have a worse prognosis. Further research to determine whether 
management guided by ultrasonic measures of congestion improves outcome is warranted. 
 
 
 
 
 
 
 
 
 
Page 16 of 23 
 
References 
1) Shoaib A, Waleed M, Khan S, Raza A, Zuhair M, Kassianides X, Djahit A, Goode 
K, Wong K, Rigby A, Clark A, Cleland J. Breathlessness at rest is not the dominant 
presentation of patients admitted with heart failure. Eur J Heart Fail. 2014;16:1283-
91.  
2) Dovancescu S, Pellicori P, Mabote T, Torabi A, Clark AL, Cleland JGF. The effects 
of short-term omission of daily medication on the pathophysiology of heart failure. 
Eur J Heart Fail. 2017;19:643-649.  
3) Braunschweig F, Linde C, Eriksson MJ, Hofman-Bang C, Rydén L. Continuous 
haemodynamic monitoring during withdrawal of diuretics in patients with congestive 
heart failure. Eur Heart J. 2002;23:59-69. 
4) Pellicori P, Cleland JG, Zhang J, Kallvikbacka-Bennett A, Urbinati A, Shah P, Kazmi 
S, Clark AL. Cardiac Dysfunction, Congestion and Loop Diuretics: their Relationship 
to Prognosis in Heart Failure. Cardiovasc Drugs Ther. 2016 ;30:599-609. 
5) Melenovsky V, Andersen MJ, Andress K, Reddy YN, Borlaug BA. 
Lung congestion in chronic heart failure: haemodynamic, clinical, and prognostic 
implications. Eur J Heart Fail. 2015;17:1161-71.  
6) Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein 
K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra 
M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad 
F, Anker SD, Rhodes A, McMurray JJ, Filippatos G; European Society of 
Cardiology; European Society of Intensive Care Medicine. Assessing and grading 
congestion in acute heart failure: a scientific statement from the acute heart failure 
committee of the heart failure association of the European Society of Cardiology and 
Page 17 of 23 
 
endorsed by the European Society of Intensive Care Medicine. Eur J Heart 
Fail. 2010;12:423-33.  
7) Gadsbøll N, Høilund-Carlsen PF, Nielsen GG, Berning J, Brunn NE, Stage P, Hein E, 
Marving J, Løngborg-Jensen H, Jensen BH. Symptoms and signs of heart failure in 
patients with myocardial infarction: reproducibility and relationship to chest X-ray, 
radionuclide ventriculography and right heart catheterization. Eur Heart J. 
1989;10:1017-28. 
8) McGee SR. Physical examination of venous pressure: a critical review. Am Heart J. 
1998;136:10-8. 
9) Drazner MH, Hellkamp AS, Leier CV, Shah MR, Miller LW, Russell SD, Young JB, 
Califf RM, Nohria A. Value of clinician assessment of hemodynamics in advanced 
heart failure: the ESCAPE trial. Circ Heart Fail. 2008;1:170-7.  
10) Pellicori P, Urbinati A, Shah P, MacNamara A, Kazmi S, Dierckx R, Zhang J, Cleland 
JGF, Clark AL. What proportion of patients with chronic heart failure are eligible for 
sacubitril-valsartan? Eur J Heart Fail. 2017;19:768-778.  
11) Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson 
PB; CHAMPION Trial StudyGroup.Sustained efficacy of pulmonary artery pressure t
o guide adjustment of chronic heart failure therapy: complete follow-up results from 
the CHAMPION randomised trial. Lancet. 2016;387:453-61.  
12) Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai 
AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O'Meara E, Rouleau 
JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay 
SM, Pitt B. Regional variation in patients and outcomes in the Treatment of Preserved 
Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. 
Circulation. 2015;131:34-42.  
Page 18 of 23 
 
13) Platz E, Merz AA, Jhund PS, Vazir A, Campbell R, McMurray JJ. Dynamic changes 
and prognostic value of pulmonary congestion by lung ultrasound in acute and 
chronic heart failure: a systematic review. Eur J Heart Fail. 2017;19:1154-1163.  
14) Platz E, Lewis EF, Uno H, Peck J, Pivetta E, Merz AA, Hempel D, Wilson C, Frasure 
SE, Jhund PS, Cheng S, Solomon SD. Detection and prognostic value of pulmonary 
congestion by lung ultrasound in ambulatory heart failure patients. Eur Heart J. 
2016;37:1244-51.  
15) Coiro S, Rossignol P, Ambrosio G, Carluccio E, Alunni G, Murrone A, Tritto 
I, Zannad F, Girerd N.Prognostic value of residual pulmonary congestion at discharge 
assessed by lung ultrasound imaging in heart failure. Eur J Heart Fail. 2015;17:1172-
81.  
16) Pellicori P, Kallvikbacka-Bennett A, Dierckx R, Zhang J, Putzu P, Cuthbert J, Boyalla 
V, Shoaib A, Clark AL, Cleland JG. Prognostic significance of ultrasound-assessed 
jugular vein distensibility in heart failure. Heart. 2015;101:1149-58.  
17) Pellicori P, Carubelli V, Zhang J, Castiello T, Sherwi N, Clark AL, Cleland JG. IVC 
diameter in patients with chronic heart failure: relationships and prognostic 
significance. JACC Cardiovasc Imaging. 2013;6:16-28.  
18) Pellicori P, Kallvikbacka-Bennett A, Khaleva O, Carubelli V, Costanzo P, Castiello T, 
Wong K, Zhang J, Cleland JG, Clark AL. Global longitudinal strain in patients with 
suspected heart failure and a normal ejection fraction: does it improve diagnosis and 
risk stratification? Int J Cardiovasc Imaging. 2014;30:69-79.  
19) Pellicori P, Kallvikbacka-Bennett A, Zhang J, Khaleva O, Warden J, Clark AL, 
Cleland JG. Revisiting a classical clinical sign: jugular venous ultrasound. Int J 
Cardiol. 2014;170:364-70.  
Page 19 of 23 
 
20) Picano E, Pellikka PA. Ultrasound of extravascular lung water: a new standard for 
pulmonary congestion. Eur Heart J. 2016;37:2097-104.  
21) Scali MC, Cortigiani L, Simionuc A, Gregori D, Marzilli M, Picano E.Exercise-
induced B-lines identify worse functional and prognostic stage in heart failure patients 
with depressed left ventricular ejection fraction. Eur J Heart Fail. 2017;19:1468-1478.  
22) Gargani L, Frassi F, Soldati G, Tesorio P, Gheorghiade M, Picano E. 
Ultrasound lung comets for the differential diagnosis of acute cardiogenic dyspnoea: 
a comparison with natriuretic peptides. Eur J Heart Fail. 2008;10:70-7. 
23) Pellicori P, Clark AL, Kallvikbacka-Bennett A, Zhang J, Urbinati A, Monzo 
L, Dierckx R, Anker SD, Cleland JGF. Non-invasive measurement of right atrial 
pressure by near-infrared spectroscopy: preliminary experience. A report from the 
SICA-HF study. Eur J Heart Fail. 2017;19:883-892. 
24) Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, Maggioni 
AP, Cook T, Swedberg K, Burnett JC Jr, Grinfeld L, Udelson JE, Zannad 
F, Gheorghiade M; EVEREST Trial Investigators. Clinical course and predictive 
value of congestion during hospitalization in patients admitted for worsening signs 
and symptoms of heart failure with reduced ejection fraction: findings from the 
EVEREST trial. Eur Heart J. 2013;34:835-43.  
25) Lala A, McNulty SE, Mentz RJ, Dunlay SM, Vader JM, AbouEzzeddine OF, DeVore 
AD, Khazanie P, Redfield MM, Goldsmith SR, Bart BA, Anstrom KJ, Felker 
GM, Hernandez AF, Stevenson LW. Relief and Recurrence of Congestion During and 
After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization 
Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and 
Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). 
Circ Heart Fail. 2015;8:741-8. 
Page 20 of 23 
 
26) Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, 
González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, 
Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, 
Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members; Document 
Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic 
heart failure: The Task Force for the diagnosis and treatment of acute and chronic 
heart failure of the European Society of Cardiology (ESC). Developed with the 
special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart 
Fail. 2016;18:891-975.  
27) Cleland JGF, Teerlink JR, Davison BA, Shoaib A, Metra M, Senger S, Milo O, Cotter 
G, Bourge RC, Parker JD, Jondeau G, Krum H, O'Connor CM, Torre-Amione G, van 
Veldhuisen DJ, McMurray JJV; VERITAS Investigators. Measurement of troponin 
and natriuretic peptides shortly after admission in patients with heart failure-does it 
add useful prognostic information? An analysis of the Value of Endothelin Receptor 
Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). Eur J Heart 
Fail. 2017;19:739-747.  
28) Cleland JG, McMurray JJ, Kjekshus J, Cornel JH, Dunselman P, Fonseca 
C, Hjalmarson A, Korewicki J, Lindberg M, Ranjith N, van Veldhuisen 
DJ, Waagstein F, Wedel H, Wikstrand J.; CORONA Study Group. Plasma 
concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: 
prediction of cardiovascular events and interaction with the effects of rosuvastatin: a 
report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). 
J Am Coll Cardiol. 2009;54:1850-9.  
29) Troughton RW, Frampton CM, Brunner-La Rocca HP, Pfisterer M, Eurlings 
LW, Erntell H, Persson H, O'Connor CM, Moertl D, Karlström P, Dahlström 
Page 21 of 23 
 
U, Gaggin HK, Januzzi JL, Berger R, Richards AM, Pinto YM, Nicholls MG. 
Effect of B-type natriuretic peptide-guided treatment of chronic heart 
failure on total mortality and hospitalization: an individual patient meta-analysis. 
Eur Heart J. 2014;35:1559-67. 
30) Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller 
N, Januzzi JL Jr, Mark DB, Piña IL, Passmore G, Whellan DJ, Yang H, Cooper 
LS, Leifer ES, Desvigne-Nickens P, O'Connor CM. Effect of Natriuretic Peptide-
Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients 
With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. 
JAMA. 2017;318:713-720.  
31) Dalen H, Gundersen GH, Skjetne K, Haug HH, Kleinau JO, Norekval TM, Graven T. 
Feasibility and reliability of pocket-size ultrasound examinations of 
the pleural cavities and vena cava inferior performed by nurses in 
an outpatient heart failure clinic. Eur J Cardiovasc Nurs. 2015;14:286-93.  
32) Futter JE, Cleland JG, Clark AL. Body mass indices and outcome in patients with 
chronic heart failure. Eur J Heart Fail. 2011;13:207-13. 
33) Zile MR, Claggett BL, Prescott MF, McMurray JJ, Packer M, Rouleau JL, Swedberg 
K, Desai AS, Gong J, Shi VC, Solomon SD. Prognostic Implications of Changes in 
N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll 
Cardiol. 2016;68:2425-2436.  
34) Pivetta E, Baldassa F, Masellis S, Bovaro F, Lupia E, Maule MM.Sources of 
Variability in the Detection of B-Lines, Using Lung Ultrasound. Ultrasound Med 
Biol. 2018;44:1212-1216.  
35) Dwyer KH, Merz AA, Lewis EF, Claggett BL, Crousillat DR, Lau ES, Silverman 
MB, Peck J, Rivero J, Cheng S, Platz E. Pulmonary Congestion by Lung Ultrasound 
Page 22 of 23 
 
in Ambulatory Patients With Heart Failure With Reduced or Preserved Ejection 
Fraction and Hypertension. J Card Fail. 2018;24:219-226.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 23 of 23 
 
Legend to figures 
 
Figure 1: Of the 187 patients with complete ultrasound data who had no clinical sign of 
congestion, 87 (47%) had at least 1 sign of congestion on ultrasound (a dilated inferior vena 
cava (IVC), greater than 20 mm, an abnormal JVD ratio (lower than 4), or B-lines greater or 
equal to the lower boundary of the highest tercile (14)). 10 (5%) patients had all three 
ultrasonic signs of congestion and the highest levels of NT-proBNP. 
 
Figure 2. Multi-panel KM for primary outcome of death from all causes (ACM) and heart 
failure hospitalizations (HFH) for each echocardiographic marker of congestion by tercile: 
IVC diameter (top-right; Tercile 1:<1.7 cm, Tercile 2:1.8-2.2 cm, Tercile 3>2.2 cm), JVD 
ratio (mid-left: Tercile 1:>6.6, Tercile 2: 4.0-6.5, Tercile 3<4), intrahepatic vein diameter 
(mid-right; Tercile 1:<0.5 cm, Tercile 2: 0.6-0.8 cm, Tercile 3>0.8 cm) and B-lines (bottom-
centre; Tercile 1:<3 B-lines, Tercile 2:4-13 B-lines, Tercile 3>14 B-lines). Also, KM curve 
for IVC collapsibility (above or below 50%) and outcome are shown (top-left).  
 
Figure 3. Multi-panel KM for primary outcome of death from all causes (ACM) and heart 
failure hospitalizations (HFH) showing additive value of measuring congestion by ultrasound 
in patients in the highest NT-proBNP tercile (>2045 ng/L).  
 



Table 1 
 
Variable 
Missing HFrEF 
LVEF <40% 
N=124 
HFmrEF# 
LVEF 40-49% 
N=68 
HFpEF# 
LVEF >50% 
N=150 
P-value 
 
Demographics 
Age – years 0 74 (64-81) 76 (68-82) 77 (69-84) 0.03 
Men – no. (%) 0 100 (81) 48 (71) 81 (54) <0.001 
NYHA I  
0 
 
16 (13) 7 (10) 27 (18)  
0.14 NYHA II 69 (55) 46 (68) 92 (61) 
NYHA III 39 (31) 15 (22) 31 (21) 
IHD – no. (%) 0 86 (69) 31 (46) 50 (33) <0.001 
DM – no. (%) 0 41 (33) 18 (27) 40 (27) 0.45 
Hypertension – no. (%) 0 54 (43) 37 (54) 97 (65) 0.002 
Smoker – no. (%) 0 17 (14) 7 (10) 19 (13) 0.79 
Atrial fibrillation – no. (%) 0 44 (36) 38 (56) 82 (55) 0.002 
COPD – no. (%) 0 24 (19) 13 (19) 29 (19) 0.99 
SBP – mmHg 0 132 (19) 141 (28) 144 (26) <0.001 
DBP – mmHg 0 72 (11) 74 (11) 76 (12) 0.052 
Heart rate – bpm 0 73 (13) 72 (16) 72 (14) 0.83 
BMI – kg/m2 0 29 (5) 30 (6) 30 (7) 0.42 
BSA – m2 0 2.0 (0.2) 1.9 (0.2) 1.9 (0.3) 0.45 
Clinical congestion 
No signs of congestion – no. (%) 0 80 (64) 39 (57) 84 (56) 0.34 
Oedema – None – no. (%) 
0 
87 (70) 44 (65) 94 (63)  
0.49 Oedema –Ankles – no. (%) 15 (12) 13 (19) 22 (15) 
Oedema ->ankles – no. (%) 22 (18) 11 (16) 34 (23) 
Lung crackles – None – no. (%) 112 (90) 59 (87) 131 (87) 
0.68 
Lung crackles – Basal – no. (%) 12 (10) 9 (13) 19 (13) 
JVP – not raised – no. (%) 99 (80) 52 (77) 121 (81)  
0.73 JVP – 1 to 4 cm – no. (%) 20 (16) 14 (21) 21 (14) 
JVP – to earlobe – no. (%) 5 (4) 2 (3) 8 (5) 
Blood tests 
Creatinine – µmol/l 0 110 (90-139) 100 (84-130) 100 (79-127) 0.05 
Urea – mmol/l 0 9.0 (6.8-12.3) 9.4 (6.9-11.9) 8.1 (6.4-11.0) 0.18 
Haemoglobin – g/dl 0 13.2 (1.7) 13.3 (1.5) 13.0 (1.8) 0.42 
Albumin – g/l 0 36 (3) 37 (3) 36 (3) 0.38 
Bilirubin – µmol/l 0 12 (9-15) 11 (9-15) 10 (8-13) 0.006 
NT-proBNP – ng/l 2 1494 (684-3502) 1330 (382-2881) 1100 (354-1994) 0.003 
NT-proBNP – ng/l (SR only) 2 1124 (436-2257) 352 (192-542) 349 (126-1172) <0.001 
Treatment 
Beta-blocker – no. (%) 0 113 (91) 58 (85) 116 (77) 0.008 
ACE-I or ARB – no. (%) 0 111 (90) 59 (87) 120 (80) 0.08 
MRA – no. (%) 0 83 (67) 38 (56) 45 (30) <0.001 
Loop diuretic – no. (%) 0 104 (84) 47 (69) 107 (71) 0.022 
LD increased – no. (%) 0 10 (8) 9 (13) 16 (11) 0.51 
LD decreased/stopped – no. (%) 0 5 (4) 3 (4) 9 (6) 0.74 
MRA added – no. (%) 0 9 (7) 4 (6) 18 (12) 0.23 
Thiazide added – no. (%) 0 2 (2) 1 (2) 2 (1) 0.98 
CRT – no. (%) 0 20 (16) 7 (10) 1 (<1) <0.001 
Echocardiography 
LVEDV – ml 0 214 (166-261) 135 (110-173) 110 (90-136) <0.001 
LVEDD – cm 0 6.2 (5.8-6.9) 5.3 (4.8-5.9) 4.9 (4.5-5.4) <0.001 
LVEF - % 0 32 (25-35) 45 (43-47) 57 (53-61) NA 
History of LVEF <40% – no. (%) 0 NA 39 (58) 45 (30) NA 
LAD – cm 0 4.6 (4.0-5.1) 4.2 (3.8-4.9) 4.3 (3.8-4.8) 0.03 
LAVI  - ml/m2 0 44 (36-57) 45 (33-63) 42 (32-55) 0.19 
Septal E/E’ 29 18 (13-24) 13 (10-18) 13 (10-16) <0.001 
Lateral E/E’ 13 13 (9-17) 10 (7-13) 10 (7-13) <0.001 
TAPSE – mm 9 1.7 (1.4-2.1) 1.9 (1.5-2.4) 2.1 (1.7-2.4) <0.001 
TR gradient – mmHg 49 29 (21-38) 30 (22-38) 29 (24-37) 0.92 
Mitral regurgitation; None/Trivial – no. (%)  
0 
50 (40) 36 (53) 76 (51)  
0.37 Mitral regurgitation; Mild– no. (%) 66 (53) 29 (43) 68 (45) 
Mitral regurgitation; >Moderate – no. (%) 8 (7) 3 (4) 6 (4) 
Tricuspid regurgitation; None/Trivial – no. (%)  
0 
65 (52) 36 (53) 80 (53)  
0.40 Tricuspid regurgitation; Mild– no. (%) 57 (46) 30 (44) 61 (41) 
Tricuspid regurgitation; >Moderate – no. (%) 2 (2) 2 (3) 9 (6) 
Congestion by ultrasound 
IVC – cm  7 2.0 (1.7-2.4) 2.0 (1.6-2.4) 2.0 (1.7-2.3) 0.98 
IVC collapse>50% – no. (%) 7 93 (76) 50 (77) 119 (80) 0.68 
Visible intrahepatic veins – no. (%) 4 93 (76) 49 (74) 130 (87) 0.035 
Max intrahepatic vein diameter - cm 4 0.7 (0.5-1.0) 0.8 (0.5-0.9) 0.7 (0.4-0.9) 0.59 
JVD Ratio  23 5.1 (2.9-6.7) 5.5 (3.1-7.3) 5.4 (3.3-7.4) 0.37 
B-lines 0 6 (2-21) 6 (2-20) 7 (2-15) 0.55 
B-lines = 0 0 17 (14) 16 (16) 28 (19) 0.54 
 
 
 
Table 1: Characteristics of patients with HF by clinical phenotype, heart failure with reduced (HFrEF), mid-range (HFmEF), or preserved 
(HFpEF) left ventricular ejection fraction (LVEF). List of abbreviation used: IHD - ischemic heart disease; DM – diabetes mellitus; COPD - 
chronic obstructive pulmonary disease; SBP - systolic blood pressure; DBP - diastolic blood pressure; BMI - body mass index; BSA – body 
surface area; NTproBNP - N-terminal B-type natriuretic peptide;; JVP - jugular venous pressure;  ACE- angiotensin-converting-enzyme 
inhibitor; ARB - Angiotensin II receptor blocker; MRA - mineralocorticoid receptor antagonist; LD – loop diuretic; CRT - cardiac 
resynchronization therapy; LVEDD - left ventricle end-diastolic diameter; LVEDV - left ventricle end diastolic volume; LAD – left atrial 
diameter; LAVI - left atrial volume index; TAPSE - Tricuspid Annular Plane Systolic Excursion; TR gradient- Trans-Tricuspid systolic gradient, 
IVC – inferior vena cava; JVD – jugular vein diameter. # includes HF with recovered LVEF for the purposes of this exercise 
 
 Correlation coefficient  
 NT-proBNP NT-proBNP  
(if in SR) 
NT-proBNP 
 (if in AF) 
JVD ratio Intrahepatic vein size IVC B-lines 
NT-proBNP – ng/l - - - -0.487*** 0.472*** 0.483*** 0.424*** 
NT-proBNP (if in SR) - - - -0.365*** 0.388*** 0.427*** 0.352*** 
NT-proBNP (if in AF) - - - -0.440*** 0.348*** 0.318*** 0.460*** 
JVD ratio - - - - -0.449*** -0.443*** -0.391*** 
Intrahepatic vein size - cm - - - - - 0.829*** 0.326*** 
IVC – cm - - - - - - 0.368*** 
Age- years  0.489*** 0.461*** 0.394*** -0.322*** 0.180** 0.219*** 0.294*** 
BMI- kg/m2 -0.159** -0.167* -0.287*** -0.024 (ns) -0.012 (ns) 0.019 (ns) -0.235*** 
SBP – mmHg 0.066 (ns) 0.123 (ns) -0.022 (ns) -0.092 (ns) -0.065 (ns) -0.003 (ns) 0.125* 
Creatinine µmol/l 0.186** 0.187* 0.291*** -0.054 (ns) 0.067 (ns) 0.057 (ns) 0.016 (ns) 
Haemoglobin – g/dl -0.248*** -0.322*** -0.341*** 0.169** -0.170** -0.170** -0.149** 
LVEF - % -0.211*** -0.343*** -0.343*** 0.086 (ns) -0.089 (ns) -0.032 (ns) -0.067 (ns) 
LA volume – ml 0.469*** 0.374*** 0.332*** -0.293*** 0.462*** 0.493*** 0.247*** 
TR gradient - mmHg 0.453*** 0.431*** 0.367*** -0.381*** 0.446*** 0.460*** 0.448*** 
 
Table 2. Correlations amongst biochemical and ultrasound measures of congestion. Correlation with other clinical, biochemical and echocardiographic 
variables of interest is also shown.  A log transformation for NTproBNP before conducting the analysis was done to satisfy the model assumptions.  Legend: 
*** p<0.001 (also shown in bold), ** p<0.01, * P<0.05, ns = p>0.05 
 
 
Variable 
Association with the Composite of First HFH or Death 
 
Multivariable analysis 
 
Models including B-Lines Models including JVD Ratio Models including IVC Model including clinical 
congestion 
HR (95% CI) 2 p-
value 
HR (95% CI) 2 p-
value 
HR (95% CI) 2 p-
value 
HR (95% CI) 2 p-value 
Age – year  a)1.01 (0.98-1.05) 
b)1.01 (0.98-1.05) 
c) 1.01 (0.98-1.05) 
0.3 
0.3 
0.3 
0.57 
0.58 
0.58 
a) 1.01 (0.97-1.05) 
b) 1.01 (0.97-1.05) 
0.2 
0.2 
0.67 
0.61 
a) 1.01 (0.98-1.05) 
b) 1.01 (0.97-1.04) 
0.4 
0.1 
0.51 
0.79 
1.01 (0.97-1.04) 0.1 0.76 
NYHA class  
(III vs. I/II)  
a) 1.70 (0.94-3.06) 
b) 1.67 (0.93-3.00) 
c) 1.69 (0.94-3.05) 
3.1 
2.9 
3.1 
0.08 
0.09 
0.08 
a) 1.33 (0.72-2.48) 
b) 1.40 (0.76-2.58) 
0.8 
1.1 
0.36 
0.29 
a) 1.69 (0.94-3.04) 
b) 1.61 (0.89-2.91) 
3.1 
2.5 
0.08 
0.11 
1.64 (0.92-2.93) 2.8 0.10 
Urea – mmol/l  a) 1.03 (0.99-1.07) 
b) 1.04 (0.99-1.08) 
c) 1.03 (0.99-1.08) 
2.3 
2.6 
2.3 
0.12 
0.11 
0.13 
a) 1.04 (1.00-1.08) 
b) 1.04 (1.00-1.09) 
3.9 
4.2 
0.048 
0.040 
a) 1.03 (0.99-1.07) 
b) 1.04 (1.00-1.08) 
2.2 
3.0 
0.14 
0.08 
1.03 (0.99-1.07) 1.8 0.18 
Haemoglobin  -g/dl a) 0.96 (0.82-1.13) 
b) 0.97 (0.83-1.14) 
c) 0.96 (0.82-1.13) 
0.2 
0.2 
0.2 
0.66 
0.69 
0.65 
a) 0.96 (0.81-1.12) 
b) 0.96 (0.81-1.13) 
0.3 
0.3 
0.58 
0.62 
a) 0.99 (0.84-1.16) 
b) 0.98 (0.84-1.15) 
0.0 
0.1 
0.90 
0.80 
0.97 (0.83-1.14) 0.1 0.72 
Log [NT-proBNP]  a) 5.18 (2.64-10.20) 
b) 5.27 (2.54-10.95) 
c) 5.25 (2.69-10.24) 
22.7 
19.8 
23.7 
<0.001 
<0.001 
<0.001 
a) 4.11 (1.99-8.45) 
b) 4.32 (2.12-8.80) 
14.7 
16.3 
<0.001 
<0.001 
a) 4.08 (2.04-8.15) 
b) 3.76 (1.85-7.64) 
15.9 
13.4 
<0.001 
<0.001 
5.09 (2.61-9.90) 22.9 <0.001 
Signs of congestion  
(vs no signs) 
- - - - - - - - - 1.70 (0.93-3.11) 3.0 0.084 
B-lines: 
Continuous variable 
Terciles (compared to T1) 
Tercile 2 
Tercile 3 
Above median (>7 vs <7) 
 
a) 1.004 (0.99-1.01) 
 b) Reference 
1.65 (0.71-3.85) 
1.54 (0.68-3.48) 
c) 1.23 (0.65-2.35) 
 
0.4 
- 
1.3 
1.1 
0.4 
 
0.51 
- 
0.25 
0.29 
0.53 
- 
 
 
- 
 
 
- 
 
 
- 
 
- 
 
 
- 
 
 
- - - 
JVD Ratio: 
Continuous variable 
- 
 
- 
 
- 
 
 
a) 0.84 (0.72-0.98) 
 
5.3 
 
0.022 
- 
 
- 
 
- 
 
- - - 
  
Table 3a:  Model A – Clinical Variables - five candidate variables of interest (age, NYHA class III vs I/II, urea, haemoglobin and log 
[NTproBNP]) were chosen prospectively in addition to clinical and ultrasound measurements of congestion. A small number of variables were 
selected to avoid over-fitting. Four separate analyses are shown to test the independent association of different clinical and ultrasound 
measurements of congestion with outcome, including B-lines (left column), JVD ratio (mid column, left), IVC diameter (mid column, right) and 
presence of clinical signs of congestion (right column). Variables independently associated with outcome are shown in bold. 
Three different models were constructed for B-lines, used as a continuous variable (a, top line), in terciles (b, mid line) or above or equal to (vs 
below) median (c, bottom line). B-lines were recorded for at least 5 beats for each chest site, but the number of B-lines might vary with time of 
acquisition. Adding heart rate to a model with B-lines as a continuous variable did not change results (only log [NT-proBNP] remained 
associated with outcome; HR (95% CI): 5.32 (2.71-10.45), p<0.001). 
Two different models were constructed for JVD ratio and IVC diameter, used as a continuous variable (a, top line), or in terciles (b, bottom line).  
 
 
 
 
Terciles (compared to T1) 
Tercile 2 
Tercile 3 
b) Reference 
1.43 (0.51-3.99) 
2.64 (1.03-6.79) 
- 
0.5 
4.0 
- 
0.49 
0.044 
 
IVC – cm: 
Continuous variable 
Terciles (compared to T1) 
Tercile 2 
Tercile 3 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
 
a) 1.78 (1.17-2.72) 
b) Reference 
1.26 (0.47-3.41) 
2.93 (1.15-7.48) 
 
7.2 
 
0.2 
5.0 
 
0.007 
 
0.64 
0.025 
- - - 
Variable 
Association with The Composite of First HFH or Death 
 
Multivariable analysis 
 
Model including B-Lines Model including JVD Ratio Model including IVC 
HR (95% CI) 2 p-value HR (95% CI) 2 p-value HR (95% CI) 2 p-value 
Age - year a) 1.02 (0.98-1.05) 
b) 1.02 (0.98-1.05) 
c) 1.02 (0.98-1.05) 
1.0 
0.9 
0.8 
0.33 
0.33 
0.35 
1.02 (0.98-1.05) 0.6 0.44 1.02 (0.98-1.05) 1.0 0.33 
Log [NT-proBNP]  a) 5.58 (2.66-11.72) 
b) 5.80 (2.69-12.48) 
c) 5.69 (2.72-11.90) 
20.6 
20.1 
21.3 
<0.001 
<0.001 
<0.001 
4.16 (1.89-9.15) 12.6 <0.001 4.80 (2.82-10.11) 17.0 <0.001 
E/E’ lateral a) 1.02 (0.98-1.05) 
b) 1.01 (0.98-1.05) 
c) 1.02 (0.98-1.05) 
0.7 
0.7 
0.8 
0.39 
0.42 
0.38 
1.02 (0.98-1.05) 0.7 0.40 1.02 (0.99-1.06) 1.6 0.21 
LAVI – ml/m2 a)1.01 (1.00-1.02) 
b) 1.01(0.99-1.01) 
c) 1.02 (0.98-1.05) 
1.3 
1.1 
0.8 
0.26 
0.29 
0.38 
1.01 (0.99-1.02) 1.0 0.32 1.01 (0.99-1.02) 0.5 0.50 
TR gradient - mmHg a) 1.00 (0.97-1.02) 
b) 1.00 (0.98-1.02) 
c) 1.00 (0.98-1.02) 
0 
0 
0 
0.83 
0.99 
0.90 
1.00 (0.97-1.02) 0 0.99 1.00 (0.97-1.02) 0 0.71 
B-lines: 
Continuous variable 
Terciles (compared to T1) 
Tercile 2 
Tercile 3 
Above median (>7 vs <7) 
 
a) 1.01 (0.99-1.02) 
b) Reference 
1.53 (0.61-3.84) 
1.52 (0.65-3.55) 
c) 1.38 (0.69-2.77) 
 
0.9 
- 
0.8 
0.9 
0.8 
 
0.36 
- 
0.36 
0.34 
0.37 
 
 
- 
- - 
 
 
- 
- - 
JVD Ratio  - - - 0.85 (0.73-0.99) 4.3 0.037 - - - 
IVC – cm - - - - - - 1.95 (1.19-3.19) 7.1 0.007 
 Table 3b:  Model B – Echocardiographic Variables - In addition to age and Log [NT-proBNP], the three echocardiographic variables that were 
most strongly associated with prognosis in univariable analysis were included in addition to ultrasound measurements of congestion. A small 
number of variables were selected to avoid over-fitting.  
Three separate analyses are shown to test the independent association of different ultrasound measurements of congestion with outcome, 
including B-lines (left column), JVD ratio (mid column), and IVC diameter (right column).  Variables independently associated with outcome 
are shown in bold.  
Three different models were constructed for B-lines, used as a continuous variable (a, top line), in terciles (b, mid line) or above or equal to (vs 
below) median (c, bottom line). 
  Discrimination Reclassification# 
Model 
No. 
Model C-statistics 
(95%CI) 
Difference cNRI (95%CI) p-value IDI (95%CI) p-value 
1 Base model*  0.74 (0.68-0.80) Compared to 1 
(p-value) 
Compared to 2a 
(p-value) 
- - - - 
2a 1 + log(NT-proBNP) 0.77 (0.71-0.83) 0.26 - 0.76 (0.41-1.11) <0.001 0.16 (0.10-0.21) <0.0001 
2b 1+ B-lines 0.75 (0.69-0.81) 0.75 - 0.35 (0.00-0.70) 0.047 0.04 (0.01-0.07) 0.027 
2c 1 + IVC 0.77 (0.71-0.83) 0.09 - 0.56 (0.21-0.91) 0.002 0.06 (0.02-0.10) 0.006 
2d 1 + JVD ratio  0.76 (0.70-0.82) 0.37 - 0.73 (0.38-1.08) <0.001 0.10 (0.04-0.15) 0.0003 
2e 1+ clinical signs of 
congestion (vs no signs) 
0.76 (0.69-0.82) 0.39 - 0.50 (0.15-0.85) 0.005 0.02 (-0.01,0.04) 0.13 
3 2a + B-lines 0.77 (0.71-0.83) 0.31 0.85 0.03 (-0.32, 0.38) 0.88 0.00 (-0.00, 0.01) 0.92 
4 2a+ IVC 0.78 (0.73-0.84) 0.09 0.11 0.08 (-0.27, 0.43) 0.65 0.01 (-0.01, 0.02) 0.45 
5 2a + JVD ratio 0.79 (0.73-0.85) 0.10 0.09 0.17 (-0.18, 0.52) 0.34 0.03 (0.00-0.06) 0.029 
6 2a+ B-lines and IVC 0.78 (0.72-0.84) 0.09 0.12 0.07 (-0.28, 0.42) 0.68 0.01 (-0.01, 0.02) 0.46 
7 2a + B-lines and JVD ratio 0.79 (0.75-0.88) 0.10 0.08 0.23 (-0.12, 0.58) 0.19 0.03 (0.01-0.06) 0.023 
 
Table 4: The model’s discrimination and reclassification.  *base model: age, sex, NYHA (III vs II/I), creatinine, haemoglobin and left 
ventricular ejection fraction (LVEF). # note that the reclassification is based on the event at 1 year (n=125 patients with 59 events) as the method 
is based on logistic regression.  
 
